AdminMed

10/03/2023

We look forward to meeting with David Young at GPT-Party this week!

Предприниматель, венчурный инвестор. Соучредитель Davidovs Venture Capital — венчурной фирмы на ранней стадии, основанной сообществом из более чем 75 основателей. Соучредите....

09/13/2023

The international group of our academic clients published the results of using AdminPen™ hollow microneedles liquid injection devices (600, 900, 1200, and 1500 μm), which were referred to as Ho-MNs in the publication, for the intradermal delivery of hypericin lipid nanocapsules (Hy-LNCs) for photodynamic therapy (PDT) against skin cancer.

Heba Abd-El-Azim, Ismaiel A. Tekko, Ahlam Ali, Alyaa Ramadan, Noha Nafee, Nawal Khalafallah, Taifur Rahman, William Mcdaid, Rania G. Aly, Lalitkumar K. Vora, Steven J. Bell, Fiona Furlong, Helen O. McCarthy, Ryan F. Donnelly, "Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer," Journal of Controlled Release, Volume 348, 2022, Pages 849-869.

Here are the identified benefits of using AdminPen™ hollow microneedles liquid injection devices (600, 900, 1200, and 1500 μm):

Efficient Intradermal Delivery: The AdminPen™ hollow microneedles (Ho-MNs) array and an in-house fabricated Ho-MN enabled efficient intradermal delivery of hypericin lipid nanocapsules (Hy-LNCs).

Improved Physicochemical Properties: The Hy-LNCs were successfully formed with desirable properties such as a particle size of 47.76 ± 0.49 nm, PDI of 0.12 ± 0.02, and a high encapsulation efficiency of 99.67% ± 0.35.

Enhanced Photoactivity: The Hy-LNCs demonstrated a 396-fold higher photoactivity compared to free hypericin.

Increased Skin Drug Deposition: The use of AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) resulted in a 7-fold higher skin drug deposition of Hy-LNCs.

Greater Cellular Uptake: The Hy-LNCs showed significantly greater cellular uptake and higher photocytotoxicity compared to free hypericin.

Remarkable Anti-tumor Effect: In vivo studies using a n**e mouse model with transplanted tumors revealed that Hy-LNCs delivered by AdminPen™ hollow microneedles liquid injection devices (Ho-MN) exhibited a significant anti-tumor destruction (85.84%) after irradiation with 595 nm.

Promising Approach for Skin Cancer Management: The combination of AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) driven delivery of Hy-LNCs followed by irradiation presents a promising minimally invasive, effective, and site-specific approach for managing non-melanoma skin cancers.

In summary, the AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) offer an efficient and effective method for intradermal delivery of hypericin lipid nanocapsules, enhancing their therapeutic potential in photodynamic therapy against skin cancer.

Click here for Full Text (PDF):

09/13/2023

Our academic clients from Mercer University and Georgia State University used the AdminPatch® 1200 microneedle array system for improving transdermal immunization with microparticulate RSV-F Virus-like Particles, as summarized in the following publication:

D’Sa, Sucheta, Kimberly Braz Gomes, Grace Lovia Allotey-Babington, Cemil Boyoglu, Sang-Moo Kang, and Martin J. D’Souza. 2022. "Transdermal Immunization with Microparticulate RSV-F Virus-like Particles Elicits Robust Immunity" Vaccines 10, no. 4: 584.

Here are the identified benefits of using the AdminPatch® 1200 microneedle array system for improving transdermal immunization with microparticulate RSV-F Virus-like Particles:

Robust Immune Responses: The study demonstrated that the transdermal delivery of RSV-F VLP (with or without MPL®) using the AdminPatch® 1200 microneedle array system has the potential to trigger robust immune responses. The transdermal delivery of RSV-F VLP + MPL® was found to be more effective in clearing lung viral loads and preventing weight loss after an RSV challenge.

Enhanced Vaccine Efficacy: At the cellular level, MPL® augmented the vaccine response in microparticulate form. This was evidenced by higher serum and lung antibody titers and lower lung viral titers in the vaccinated groups.

Non-Invasive and Pain-Free Vaccination: The AdminPatch® 1200 microneedle array system offers a non-invasive and pain-free form of vaccination. Due to the short needle lengths, microneedles do not stimulate the nerve endings in the dermis, making the vaccination process more comfortable for the recipient.

Improved Antigen Presentation and Recognition: The study hypothesized that the transdermal delivery of a novel vaccine via the incorporation of a viral antigen such as the RSV fusion (F) protein VLPs in a polymeric matrix might result in enhanced uptake by immune cells. This could also provide improved antigen presentation and recognition by the immune system.

Advantages of Transdermal Delivery: The transdermal route has gained popularity due to its advantages related to patient compliance, ease of administration, lower doses, and the ability to benefit from the immunocompetence of the skin. In transdermal vaccination, dendritic cells and Langerhans cells residing in the dermis can engulf the antigen, leading to the activation of cellular immunity.

Microneedle Patch Acceptability: The minimally-invasive delivery of vaccines via a microneedle patch, such as the AdminPatch® 1200, would be greatly acceptable for individuals, especially children with a phobia of needles.

In conclusion, the AdminPatch® 1200 microneedle array system offers a promising approach for the transdermal delivery of the RSV-F VLP microparticulate vaccine, potentially leading to robust immune responses and enhanced vaccine efficacy.

Click here for Full Text (PDF):

09/13/2023

AdminPatch 600, 777, and 1200 microneedle arrays were successfully used for the delivery of resveratrol for breast cancer therapy, as shown in the following publication:

Shivaprasad Gadag, Reema Narayan, Archana S. Nayak, Diana Catalina Ardila, Shilpa Sant, Yogendra Nayak, Sanjay Garg, Usha Y. Nayak, "Development and preclinical evaluation of microneedle-assisted resveratrol loaded nanostructured lipid carriers for localized delivery to breast cancer therapy," International Journal of Pharmaceutics, Volume 606, 2021, 120877.

The demonstrated benefits of the AdminPatch 600, 777, and 1200 microneedle arrays (denoted as 600 MN, 777 MN, and 1200 MN in the manuscript) are the following:

Localized Delivery: The microneedle array system facilitates the localized delivery of resveratrol (RVT) to breast tissues. This targeted approach ensures that the drug is delivered directly to the affected area, increasing its therapeutic efficacy.

Improved Permeation: The study found that RVT delivered using the microneedle array AdminPatch 1200 showed a higher permeation of RVT across the skin compared to pure RVT. This suggests that the microneedle system enhances the skin's permeability to the drug.

Reduced Skin Retention: The RVT-NLCs (nanostructured lipid carriers) delivered using the microneedle array AdminPatch 1200 resulted in lower skin retention compared to pure RVT. This means that more of the drug is able to pe*****te deeper tissues rather than remaining on the skin's surface.

Enhanced Anticancer Activity: The RVT-NLCs showed higher anticancer activity on MDA-MB-231 breast cancer cell lines compared to pure RVT. This indicates that the combination of the microneedle system and the nanostructured lipid carriers enhances the drug's ability to combat cancer cells.

Inhibition of Cancer Cell Migration: The RVT-NLCs were found to inhibit the migration of MDA-MB-231 breast cancer cell lines. This suggests that the treatment not only kills cancer cells but also prevents them from spreading.

Increased Drug Concentration: Preclinical studies demonstrated that RVT-NLCs delivered via microneedles resulted in a remarkable increase in the Cmax (maximum serum concentration), Tmax (time to reach maximum concentration), and AUC0-inf (area under the curve, indicating overall drug exposure). Additionally, there was a higher localization of the drug in breast tissue compared to pure RVT administered orally.

Effective Strategy for Breast Cancer Therapy: The results suggest that administering RVT-NLCs using the AdminPatch microneedle array system is an effective strategy for localized delivery of RVT for breast cancer therapy.

The AdminPatch microneedle arrays, specifically the AdminPatch 600, AdminPatch 777, and AdminPatch 1200, offer several benefits in the delivery of resveratrol for breast cancer therapy. These benefits include improved drug permeation, reduced skin retention, enhanced anticancer activity, and increased drug concentration in the target area.

Click here for Full Text (PDF):